Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhiyu Tang

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
British Journal of Cancer|December 21, 2021
Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumoursJason D Lickliter, Mark Voskoboynik, Linda Mileshkin, et al.
Cell Biochemistry and Biophysics|October 26, 2005
TFAR19 gene changes the biophysical properties of murine erythroleukemia cellsLi Gu, Yuhui Jiang, Ying Wang, et al.
Leukemia & Lymphoma|February 8, 2020
A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairmentYing C Ou, Richard A Preston, Thomas C Marbury, et al.
Clinical and Translational Science|March 8, 2020
No QTc Prolongation With Zanubrutinib: Results of Concentration-QTc Analysis From a Thorough QT Study in Healthy SubjectsSong Mu, Borje Darpo, Zhiyu Tang, et al.
Chinese Journal of Natural Medicines|February 18, 2026
Structural basis of the major TMPRSS2 promoter G-quadruplex and its complex with berberineZhiyu Tang, Yuting Bian, Shangran Li, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 4, 2022
Model-based population pharmacokinetic analysis of tislelizumab in patients with advanced tumorsNageshwar Budha, Chi-Yuan Wu, Zhiyu Tang, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 12, 2025
Quantitative Systems Pharmacology Model to Predict Target Occupancy by Bruton Tyrosine Kinase Inhibitors in Patients With B-Cell MalignanciesOleg Demin, Ying Ou, Galina Kolesova, et al.
Journal of Biomechanics|September 22, 2009
Ryanodine receptor 1 mediates Ca2+ transport and influences the biomechanical properties in RBCsXianwei Wang, Xi Chen, Zhiyu Tang, et al.
Angewandte Chemie (International Ed. in English)|March 7, 2026
Oxidative Damage Fine-Tunes G-Quadruplex Structures in Human Gene PromotersYu Wang, Yingying Wang, Rongshuang Cheng, et al.
Clinical and Translational Science|March 22, 2024
Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumorsTian Yu, Xiangyu Liu, Chi-Yuan Wu, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
British Journal of Cancer|December 21, 2021
Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumoursJason D Lickliter, Mark Voskoboynik, Linda Mileshkin, et al.
Cell Biochemistry and Biophysics|October 26, 2005
TFAR19 gene changes the biophysical properties of murine erythroleukemia cellsLi Gu, Yuhui Jiang, Ying Wang, et al.
Leukemia & Lymphoma|February 8, 2020
A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairmentYing C Ou, Richard A Preston, Thomas C Marbury, et al.
Clinical and Translational Science|March 8, 2020
No QTc Prolongation With Zanubrutinib: Results of Concentration-QTc Analysis From a Thorough QT Study in Healthy SubjectsSong Mu, Borje Darpo, Zhiyu Tang, et al.
Chinese Journal of Natural Medicines|February 18, 2026
Structural basis of the major TMPRSS2 promoter G-quadruplex and its complex with berberineZhiyu Tang, Yuting Bian, Shangran Li, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 4, 2022
Model-based population pharmacokinetic analysis of tislelizumab in patients with advanced tumorsNageshwar Budha, Chi-Yuan Wu, Zhiyu Tang, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 12, 2025
Quantitative Systems Pharmacology Model to Predict Target Occupancy by Bruton Tyrosine Kinase Inhibitors in Patients With B-Cell MalignanciesOleg Demin, Ying Ou, Galina Kolesova, et al.
Journal of Biomechanics|September 22, 2009
Ryanodine receptor 1 mediates Ca2+ transport and influences the biomechanical properties in RBCsXianwei Wang, Xi Chen, Zhiyu Tang, et al.
Angewandte Chemie (International Ed. in English)|March 7, 2026
Oxidative Damage Fine-Tunes G-Quadruplex Structures in Human Gene PromotersYu Wang, Yingying Wang, Rongshuang Cheng, et al.
Clinical and Translational Science|March 22, 2024
Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumorsTian Yu, Xiangyu Liu, Chi-Yuan Wu, et al.
Pageof 6